Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 03, 2021

SELL
$5.02 - $6.59 $79,848 - $104,820
-15,906 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$5.79 - $8.6 $92,095 - $136,791
15,906 New
15,906 $105,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Wade G W & Inc Portfolio

Follow Wade G W & Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wade G W & Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wade G W & Inc with notifications on news.